GlaxoSmithKline plc (ADR) (GSK), Eli Lilly & Co. (LLY): This Week in Biotech

Lilly expects to take a $30 million writedown related to the discontinuation of its study. With late-stage failures piling up for Eli Lilly & Co. (NYSE:LLY) (let’s not forget how disappointing the results were for its late-stage Alzheimer’s drug solanezumab) and patent expirations growing in number, I still feel confident in labeling Lilly pharma’s most perilous pipeline.

The article This Week in Biotech originally appeared on is written by Sean Williams.

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.